Immix Biopharma Inc.

09/29/2026 | Press release | Distributed by Public on 09/29/2026 05:08

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Immix Biopharma Inc. published this content on September 29, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 29, 2026 at 11:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]